severe vertigo; dizzy; couldn’t walk; couldn’t see, vision was really blurry; Rear occipital stroke; This is a spontaneous report received from an Other HCP. A 33-year-old male patient received BNT162b2 (BNT162B2 NOS), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient’s relevant medical history and concomitant medications were not reported. The following information was reported: CEREBROVASCULAR ACCIDENT (disability, medically significant) with onset 25Mar2023, outcome “recovering”, described as “Rear occipital stroke”; VISION BLURRED (non-serious) with onset Jun2023, outcome “recovering”, described as “couldn’t see, vision was really blurry”; GAIT DISTURBANCE (non-serious) with onset Jun2023, outcome “recovering”, described as “couldn’t walk”; DIZZINESS (non-serious) with onset Jun2023, outcome “recovering”, described as “dizzy”; VERTIGO (non-serious) with onset Jun2023, outcome “recovering”, described as “severe vertigo”. The patient underwent the following laboratory tests and procedures: numerous tests and studies: Unknown results. Clinical course: Patient initially suffered two cryptogenic strokes back in April, caller then checked and clarified and confirmed the two strokes were rear occipital strokes. First stroke occurred 25Mar2023, second stroke occurred 05Jun2023. Called to report, has gone through numerous tests and studies, doctors cannot figure out what caused. With first stroke, fainted, lost consciousness, was out for over a minute. With second stroke had severe vertigo, became dizzy, was dizzy for about three weeks nonstop, couldn’t walk, was in bed two and a half weeks, couldn’t see, vision was really blurry, wasn’t stable, couldn’t focus on anything for about a month. Would say disabling as well, hard to say whether life threatening, hard to say if life threatening, any time you have a stroke is life threatening. The information on the batch/lot number for BNT162b2 will be requested and submitted if and when received.; Sender’s Comments: The association between the event rear occipital stroke with BNT162b2 NOS can not be fully excluded based on the limited information. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.